IGC Pharma (IGC) Osake Kurssi
IGC Pharma Kurssi
IGC Pharman liikevaihto on supistunut 3,3 % vuodessa viimeisten 18 vuoden aikana 1,19 M USD:een. IGC Pharman nettomarginaali −552,1 % on noussut verrattuna −3 782,4 %:iin muutama vuosi sitten.
IGC Pharma osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
IGC Pharma liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset IGC Pharma -osakkeesta
The business model of India Globalization Capital Inc (IGC) revolves around various sectors, including infrastructure, technologies, and pharmaceuticals. IGC primarily focuses on the development and commercialization of cannabis-based therapies to address various medical conditions. By leveraging their in-house research and expertise, IGC aims to create innovative cannabis formulations that can potentially improve patient outcomes and quality of life. Additionally, the company also engages in the leasing of heavy equipment, mining exploration, and reclamation of high-grade iron ore to generate sustainable revenue. Through their diversified business segments, IGC strives to deliver value to its shareholders and contribute to the evolving medical and infrastructure sectors.
India Globalization Capital Inc is primarily active in the industries of infrastructure, real estate, and pharmaceuticals.
The main competitors of India Globalization Capital Inc in the market include companies such as Canopy Growth Corporation, Aurora Cannabis Inc, and Tilray Inc. These companies operate in the same industry and compete with India Globalization Capital Inc in areas such as cannabis-based pharmaceuticals, and alternative therapies and treatment solutions. India Globalization Capital Inc aims to differentiate itself through its proprietary intellectual property and innovative approaches in the market. However, it faces strong competition from these established players who also have a significant market presence and drive advancements in the industry.
India Globalization Capital Inc. (IGC) is a prominent company founded in 2005. The company primarily operates in various sectors like infrastructure, plant extraction, and traditional Chinese medicine. With a vision to become a global leader, IGC focuses on informational technology-related products and services to fulfill evolving market needs. Throughout its history, IGC has successfully developed and commercialized a range of patented therapies, enhancing consumer healthcare experiences and quality of life. The company's commitment to innovation and diversified business portfolio have contributed to its substantial growth and recognition within the industry. IGC continues to strive towards providing cutting-edge solutions and driving positive advancements in various fields of operation.
India Globalization Capital Inc (IGC) has achieved several significant milestones over the years. One of the notable achievements is the company's entry into the medical cannabis market. By leveraging its expertise in plant-based therapies and advanced pharmaceutical technologies, IGC has developed a portfolio of cannabinoid-based combination therapies. This pioneering move has positioned the company uniquely in the industry, creating opportunities for substantial growth and market penetration. Moreover, IGC has successfully obtained multiple patents and intellectual property rights, solidifying its position as a leading player in the medical cannabis space. The company's dedication to innovation and strategic partnerships has enabled it to pave the way for novel treatments and carve a niche for itself in the market.
India Globalization Capital Inc (IGC) is primarily present in India and the United States. With its headquarters in Bethesda, Maryland, USA, IGC operates in various states across India and has a significant presence in its home country. The company focuses on developing and commercializing cannabis-based pharmaceutical and natural wellness products, as well as providing services to the telecommunications and infrastructure sectors. As a global player, IGC aims to leverage its expertise and strategic partnerships to expand its presence in other regions and countries, capitalizing on emerging market opportunities worldwide.
India Globalization Capital Inc (IGC) represents a strong commitment to innovation, growth, and value creation. With a focus on rapidly expanding markets, IGC leverages its expertise in developing and commercializing transformative products and solutions. The company's corporate philosophy centers around delivering exceptional shareholder value, fostering long-term partnerships, and adhering to the highest standards of corporate governance and ethics. By staying attuned to market trends and continuously enhancing its offerings, IGC stands as a leading player in sectors like cannabis-based therapies, specialty pharmaceuticals, and infrastructure. IGC's dedication to excellence and strategic approach underscores its mission to enhance the lives of millions through pioneering technologies and forward-thinking strategies.
5 analyytikkoa arvioi tällä hetkellä IGC Pharma-osaketta: 4 suosittaa ostoa, 1 pitoa ja 0 myyntiä.
Nykyisellä valuuttakurssilla IGC Pharma-osake noteerataan hintaan 0,17 EUR (0,19 USD).
IGC Pharma-osake (IGC) on listattuna 3 pörssissä, muun muassa: Frankfurt (IGS1.F), München (IGS1.MU).
India Globalization Capital Inc. is a diversified company that operates in various industries including construction and infrastructure, heavy industry, agricultural and food production, as well as dietary supplements.
liikevaihto IGC Pharma on 1,19 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
voitto IGC Pharma on −6,55 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
IGC Pharma:n hinta-voitto-suhde (P/E) on tällä hetkellä −2,95. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan IGC Pharma-osakkeen arvostusta.
IGC Pharma:n hinta-myynti-suhde (P/S) on tällä hetkellä 16,30. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii IGC Pharma-osakkeen arvostuskennuslukuna.
IGC Pharma:n Eulpool-laatuscore on 4/10.
IGC Pharma:n ISIN on US45408X3089. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
IGC Pharma:n WKN on A1T87A. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
IGC Pharma:n ticker on IGC. Tämä pörssinoteeraus käytetään IGC Pharma-osakkeiden kauppaan pörssissä.
IGC Pharma osake
IGC Pharma vertaisryhmä
IGC Pharma Ticker
IGC Pharma FIGI
Kaikki tunnusluvut ja syvällinen analyysi IGC Pharma:sta
Meidän osakeanalyysimme IGC Pharma-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut IGC Pharma:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: